Juno Therapeutics Announced that its Investigational Chimeric Antigen Receptor (CAR) T Cell Product Candidates are Demonstrating Encouraging Clinical Outcomes for Adults, Children with B-cell Malignancies; Data to be Presented at #ASCO16